Profile

As a world-class CDMO, the organization relentlessly strives to deliver improved health outcomes for the patients it serves by combining its experience and expertise in science, manufacturing, and technology with exceptional customer service.

Visit www.pci.com

Key Products

Drug Development & Manufacturing

PCI is a leader in innovation and expertise, offering comprehensive formulation development services, including in-house analytical development for both sterile and non-sterile dosage forms. Its scalable development and manufacturing capabilities encompass tablets, capsules, gels, ointments, liquids, sterile dosage forms, and lyophilized drug products, enabling the delivery of life-changing therapies to patients from early-phase clinical trials to commercialization.

Clinical Trial Services

PCI delivers global clinical trial services with a localized focus, managing over 200 protocols annually across more than 100 countries. By leveraging best-in-class technologies and experienced, dedicated teams, PCI ensures seamless support for the global supply of investigational medicines. This includes pharmaceutical development, clinical drug product manufacturing, packaging, labeling, storage, distribution, and comprehensive returns services.

Commercial Packaging

PCI’s commercial packaging services prioritize customer focus and flexibility, addressing the unique requirements of diverse product types and global markets. Through state-of-the-art packaging technologies, PCI offers advanced primary, secondary, and tertiary packaging solutions. These encompass a wide range of dosage forms, including oral solids, powders, liquids, creams, gels, as well as specialized injectable and parenteral delivery forms such as vials, cartridges, prefilled syringes, and auto-injectors.

Key Executives

• Salim Haffar, CEO


• Tom DeWeerdt, Chief Financial Officer


• Angi Calkins, Chief Human Resources Officer


• Jeannie Metzinger, Chief Compliance and Quality Officer


• Brad Payne, Chief Operating Officer


• John Ross, SVP Development and Manufacturing


• Tim Roberts, Chief Commercial Officer


• John Cullivan, Chief Corporate Development Officer


• Wayne Hull, Chief Digital & Technology Officer


• Ed Malatesta, SVP, Global Sales, Commercial Packaging


• Brian Keesee, SVP Clinical Trial Services


• Gil Valadez, SVP Commercial Packaging Technology

Customer Insights

Best-in-class Capabilities and Quality

Customers recognize PCI for superior packaging capabilities among competitors and our ability to tailor solutions around unique packaging requirements. Our expertise and delivery is “second-to-none” when it comes to Package Design and Development as well as Project Management support for new products coming to market.

Quality is non-negotiable for our customers which has been recognized as a clear strength at every PCI location among our global network along with GMP compliance. With over 130 successful regulatory inspections covering all major, global regulatory agencies over the last five years, our demonstrable track record in quality is central to our service offering, to ensure the safety of patients world-wide.

Investors

• Kohlberg & Company


• Mubadala Investment Company and Partners Group

Corporate Responsibility

For over 50 years, PCI has supported the delivery of life-changing therapies to patients, embracing this responsibility with passion and humility. Guided by values such as accountability, flexibility, and excellence, PCI partners with customers to manufacture critical medications for both clinical trials and public use.

PCI’s Environmental, Social, and Governance (ESG) strategy reflects its core values and commitment to customers, communities, and the planet while maintaining its critical role in the pharmaceutical supply chain. Recognizing the societal importance of its work, PCI is dedicated to ensuring the sustainability of its operations.

ESG principles are deeply embedded in PCI’s daily operations, empowering employees at every site to make a positive impact by transforming ideas into actionable outcomes. The company’s robust ESG program is structured around nine impact categories, supported by a global governance network of over 100 representatives spanning all sites and job functions. As a world-leading CDMO, PCI drives progress by aligning KPIs, targets, and sustainability frameworks with stakeholder priorities. The company’s ESG goals emphasize inclusivity, authenticity, ambition, and results-driven initiatives.

Current ESG efforts include long-standing support for STEM projects in local communities, collaborations with suppliers and partners to advance sustainable packaging solutions, and reducing waste sent to landfills. PCI is also committed to climate action, actively working to reduce its carbon footprint and contributing to global efforts to halve emissions by 2030.

PCI measures its progress both locally and globally, understanding that impactful work in smaller communities contributes to broader global change. The company’s focus on ESG is outlined in its inaugural ESG Report, which details its approach, processes, and evolving targets. PCI remains committed to transparency, continuous learning, and improvement as it advances its ESG initiatives.